** Drug developer Eton Pharmaceuticals' ETON.O shares rise 6.2% to $15.51 premarket

** Company says its experimental drug, ET-600, passed a bioequivalence study against an FDA-approved reference product with the same active ingredient for treatment of a rare condition called central diabetes insipidus $(CDI.NZ)$

** A bioequivalence study compares a generic test formulation with the original reference drug

** CDI is an uncommon problem in which the body can't properly balance fluid levels prompting to make large amounts of urine

** Eton Pharma plans to file FDA marketing application in April 2025

** As of last close, company's shares have more than tripled in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))